Skip to main content
Figure 3 | Journal of Experimental & Clinical Cancer Research

Figure 3

From: Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases

Figure 3

Synergy of the short-time (72 hrs.) sequential combined enzyme/prodrug treatment in vitro. A; C; E: Fluorimetric assay was used for evaluation of the efficacy of the treatment. Relative fluorescence corresponds to the proportion of viable cells. Fluorescence in cocultures without prodrugs was set to 100% by default. Results are presented as mean of quadruplicates. SD are stated in the tables below charts. B; D; F: Data obtained by fluorimetric assay were subsequently analyzed by Calcusyn software, and Fa-CI plots were created – CI (combination index) on the y-axis is a function of effect level (fraction affected, fa) on the x-axis (fa = 1 - % of viable cells/100). Plots display synergism (CI < 1), additivity (CI = 1) or antagonism (CI > 1) for the entire spectrum of effects [14].

Back to article page